Executive interview – VolitionRx: Results from asymptomatic CRC trial reported

Published on 20 March 2018
 

VolitionRx recently announced the initial results from a 680-sample study taken from asymptomatic colorectal cancer (CRC) patients. The study demonstrated 80% sensitivity against stage 1 CRC and 66% against high-risk adenomas (at 78% specificity). The company has stated that it is moving on to the 4,300-sample study to determine the final test panel for European launch (results in Q218). This will be followed by a 12,000+ sample blinded study which is expected to complete in H218.

Share this with friends and colleagues